Author:
Heimes Britta,Lommatzsch Albrecht,Zeimer Meike,Gutfleisch Matthias,Spital Georg,Dietzel Martha,Pauleikhoff Daniel
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology
Reference10 articles.
1. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New Engl J Med 355:1432–1444
2. EMEA (2007) Lucentis: Scientific Discussion http://www.ema.europa.eu/humandocs/PDFs/EPAR/lucentis/H-715-en6.pdf . Accessed 16 May 2010
3. EMEA (2007) Lucentis: Summary of product characteristics http://www.ema.europa.eu/humandocs/PDFs/EPAR/lucentis/emea-combined-h715en.pdf . Accessed 16 May 2010
4. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583
5. Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Schmidt-Erfurth U, Wolf S, Markabi S, Schmidli H, Weichselberger A (2010) The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 51:405–412
Cited by
49 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献